

RESEARCH ARTICLE

Open Access

Effect of hypoxia on the expression of α B-crystallin in head and neck squamous cell carcinoma

Chantal van de Schootbrugge¹, Elisabeth MJ Schults¹, Johan Bussink², Paul N Span², Reidar Grénman³, Ger JM Puijn¹, Johannes HAM Kaanders² and Wilbert C Boelens^{1*}

Abstract

Background: The presence of hypoxia in head and neck squamous cell carcinoma (HNSCC) is associated with therapeutic resistance and increased risk of metastasis formation. α B-crystallin (HspB5) is a small heat shock protein, which is also associated with metastasis formation in HNSCC. In this study, we investigated whether α B-crystallin protein expression is increased in hypoxic areas of HNSCC biopsies and analyzed whether hypoxia induces α B-crystallin expression *in vitro* and in this way may confer hypoxic cell survival.

Methods: In 38 HNSCC biopsies, the overlap between immunohistochemically stained α B-crystallin and pimonidazole-adducts (hypoxiamarker) was determined. Moreover, expression levels of α B-crystallin were analyzed in HNSCC cell lines under hypoxia and reoxygenation conditions and after exposure to reactive oxygen species (ROS) and the ROS scavenger N-acetylcysteine (NAC). siRNA-mediated knockdown was used to determine the influence of α B-crystallin on cell survival under hypoxic conditions.

Results: In all biopsies α B-crystallin was more abundantly present in hypoxic areas than in normoxic areas. Remarkably, hypoxia decreased α B-crystallin mRNA expression in the HNSCC cell lines. Only after reoxygenation, a condition that stimulates ROS formation, α B-crystallin expression was increased. α B-crystallin mRNA levels were also increased by extracellular ROS, and NAC abolished the reoxygenation-induced α B-crystallin upregulation. Moreover, it was found that decreased α B-crystallin levels reduced cell survival under hypoxic conditions.

Conclusions: We provide the first evidence that hypoxia stimulates upregulation of α B-crystallin in HNSCC. This upregulation was not caused by the low oxygen pressure, but more likely by ROS formation. The higher expression of α B-crystallin may lead to prolonged survival of these cells under hypoxic conditions.

Keywords: CRYAB protein, HspB5, Carcinoma, Squamous cell of head and neck, Hypoxia, Reactive oxygen species, Hypoxic cell survival

Background

In solid tumors, hypoxic regions can be present when cells are exposed to an oxygen pressure below 5 to 10 mmHg (0.66 – 1.32% O₂) [1]. Hypoxia can be a result of insufficient oxygen transportation to remote parts of a tumor, caused by deficient blood vessel formation (chronic, diffusion-limited hypoxia) or leaking or partially blockage of blood vessels (acute, perfusion-limited hypoxia) [1]. Hypoxia might be intermittent when the blood flow is restored after temporary vascular shutdown, which can

result in a cycling pattern of hypoxia and reoxygenation [2-4]. The presence of hypoxic regions in the tumor is detrimental for the patient, since hypoxic tumor cells are associated with therapeutic resistance and metastatic progression [5-7]. Despite the low oxygen levels, hypoxia is also associated with the presence of reactive oxygen species (ROS) [8-10]. As ROS are conventionally thought to be cytotoxic and mutagenic, they could lead to cancer progression and might be one of the reasons why the presence of hypoxia is as a bad prognostic factor [11].

α B-crystallin is a small heat shock protein, which can bind to partially unfolded proteins, thereby keeping them in a soluble state to prevent their aggregation [12,13]. It may protect cells from death induced by

* Correspondence: w.boelens@ncmls.ru.nl

¹Department of Biomolecular Chemistry, Institute for Molecules and Materials and Radboud Institute for Molecular Life Sciences, Radboud University Nijmegen, 271, RIMLS, PO Box 9101, 6500 HB Nijmegen, The Netherlands
Full list of author information is available at the end of the article

accumulation of unfolded proteins [14]. Furthermore, α B-crystallin may confer stress resistance to cells by inhibiting the processing of the pro-apoptotic protein caspase-3 [15]. Besides being mainly expressed in eye lens and muscle tissues [16], α B-crystallin can also be found in several types of cancer, among which head and neck squamous cell carcinoma (HNSCC) [17-19] and breast carcinomas [20-22]. α B-crystallin expression is associated with metastasis formation in HNSCC and in breast carcinomas [19,23] and in other types of cancer, expression is often correlated with poor prognosis as well [12,13]. The expression of α B-crystallin can be increased during various stresses, like heat shock, osmotic stress or exposure to heavy metals [24]. Moreover, in tissues from newborn piglets, α B-crystallin has been shown to be upregulated by hypoxia [25,26]. In this study, we analyzed whether the expression of α B-crystallin protein is affected in hypoxic regions of HNSCC's and whether α B-crystallin knockdown influences cell survival under hypoxic stress.

Methods

Patients

Biopsy material of 38 HNSCC patients with stage II to IV primary squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx was used (not all biopsies of the available cohort could be used due to the lack of material) [19,27]. Two hours before biopsies were taken (1 per patient), patients received 500 mg/m² body surface of the hypoxia marker pimonidazole (intravenously, dissolved in 100 ml 0.9% NaCl) over 20 minutes. The obtained biopsies were snap-frozen and stored in liquid nitrogen until immunohistochemical processing. Approval from the ethics committee of Radboud University Nijmegen Medical Centre was obtained and all patients provided written informed consent.

Immunohistochemistry

Sections of the biopsies (5 μ m) were mounted on poly-L-lysine coated slides, fixed for 10 minutes in acetone at 4°C and rehydrated in PBS. The sections were incubated overnight at 4°C with 100-fold diluted α B-crystallin antiserum [28] and subsequently incubated for 30 minutes at 37°C with 600-fold diluted FabCy3 goat- α -rabbit IgG (Jackson Immuno Research Laboratories Inc) in PBS for 45 minutes at 37°C with 10-fold diluted endothelium antibody PAL-E (Euro Diagnostica BV) in Primary Antibody Diluent (PAD, Dako) and for 60 minutes at 37°C with 100-fold diluted Alexa 647 chicken- α -mouse IgG (Molecular probes) in PBS. For visualization of the pimonidazole adducts, the sections were stained with 1000-fold diluted rabbit- α -pimonidazole (gift from Dr. James A. Raleigh, University of North Carolina), diluted in PAD for 30 minutes at 37°C and subsequently stained with 600-fold diluted Alexa 488 donkey- α -rabbit

IgG (Molecular probes) in PBS 30 minutes at 37°C. During the latter step only the rabbit antibodies directed to pimonidazole were stained [29]. Between the incubations, 3 times 2 minutes washing steps in PBS were performed. The sections were mounted using fluorostab (ProGen Biotechnik GmbH).

Image acquisition

Scanning of the biopsy sections was performed with a fluorescence microscope (Axioskop, Zeiss) and a computer-controlled motorized stepping stage, using IP-lab software (Scanalytics), as described previously [30]. Each section was completely sequentially scanned for α B-crystallin, pimonidazole and blood vessel staining at 100 \times magnification. The resulting composite grey scale images were converted to binary images for further analysis. Thresholds were set just above the background staining for each individual staining. The total tumor area was contoured manually, excluding nontumor tissue, large necrotic areas and artifacts. The percentage of α B-crystallin in the normoxic area was determined as the pimonidazole-negative tumor area containing α B-crystallin relative to the total pimonidazole-negative tumor area. The percentage of α B-crystallin in the hypoxic area was determined as the tumor area positive for α B-crystallin and pimonidazole relative to the total pimonidazole-positive area.

α B-crystallin mRNA expression upon hypoxia

The HNSCC cell line UT-SCC-5 (described in [31]), maintained in DMEM + GlutaMAX (Invitrogen) supplemented with 10% fetal calf serum (Gibco-BRL) was seeded on 6-wells plates, 0.5×10^6 cells per well, N = 4 per time point, and transferred after 24 hours from a standard humidified 37°C incubator to a humidified 37°C H35 hypoxystation (Don Whitley Scientific) with 0.1% O₂. Samples were harvested after 0–22 hours of hypoxic incubation for quantitative RNA analysis.

α B-Crystallin mRNA expression upon hypoxia, reoxygenation and N-acetylcysteine

The HNSCC cell lines UT-SCC-5 and UT-SCC-15 (described in [31]), maintained in DMEM + GlutaMAX supplemented with 10% fetal calf serum were seeded in 6-wells plates, 0.3×10^6 cells per well, N = 4 per condition, and transferred after 24 hours from a standard humidified 37°C incubator to a H35 hypoxystation with 0.1% O₂ (Don Whitley Scientific), or maintained in a standard incubator. Normoxic and hypoxic samples were harvested after 48 hours for quantitative RNA analysis. The reoxygenation samples were transferred after 24 hours of hypoxic incubation to a standard incubator again for 24 hours and subsequently harvested. To reduce ROS, cells were incubated after 24 hours of hypoxia

or normoxia with 0.05 mM NAC (Sigma). After NAC was added, the reoxygenation samples were transferred from the hypoxystation to a standard humidified 37°C incubator and incubated for 24 hours and subsequently harvested.

αB-crystallin protein expression upon hypoxia and reoxygenation

The UT-SCC-5 cell line was seeded in T25 flasks, 0.9×10^6 cells per flask, $N = 3$ for the normoxic condition and $N = 4$ for the hypoxic and reoxygenation condition, and incubated for 5 hours in a standard humidified 37°C incubator. The cells were transferred to the hypoxystation maintained at 0.1% or kept in the standard incubator and harvested after 48 hours. The reoxygenation samples were transferred after 24 hours of hypoxic incubation to the standard incubator again for 24 hours and subsequently harvested. The cells were harvested in 2% sodium dodecyl sulfate (Gibco), heated for 5 minutes at 100°C and sonicated 5×30 seconds on and 30 seconds off with Bioruptor (Diagenode). The protein concentrations were determined with BCA Protein Assay Kit (Thermo Scientific) according to manufacturer's protocol. Protein samples (60 μg/sample) were separated by electrophoresis on a 12.5% polyacrylamide gel and transferred to a nitrocellulose membrane (Protran). The membranes were blocked with 5% Elk (Campina) in PBS for an hour and washed 3 times for 10 minutes with PBS + 0.0025% v/v Nonidet P-40. The membranes were incubated for an hour with the 200-fold diluted monoclonal mouse-α-human-αB-crystallin (RIKEN) and 6000-fold diluted mouse-α-human-γ-tubulin as nce (Sigma-Aldrich) diluted in 0.025% w/v Nonidet P-40 and completed with 2% Elk in PBS. After washing, blots were incubated for 1 hour with a 6000-fold dilution of IRDye 800CW goat-α-mouse IgG (LI-COR). The proteins were visualized with the Odyssey scanner (LI-COR). Analysis was performed using Odyssey 2.1 software.

αB-crystallin mRNA expression upon H₂O₂-induced oxidative stress

UT-SCC-5 cells were seeded in 6-wells plates, 0.5×10^6 cells per well; $N = 4$ per concentration maintained in DMEM + GlutaMAX supplemented with 10% fetal calf serum. After 24 hours, cells were incubated with 0 mM (mock), 0.3 mM, 1.5 mM or 3.0 mM H₂O₂ for 1 hour after which they were incubated again in normal medium and harvested after 7 hours for quantitative RNA analysis.

Hypoxia survival upon siRNA-mediated knock-down of αB-crystallin

4.4×10^6 UT-SCC-5 cells were seeded in a T175 culture flask and maintained in DMEM + GlutaMAX supplemented with 10% fetal calf serum. After 24 hours, cells were transfected with siRNA using Lipofectamine 2000

Reagent according to manufacturers' protocol (Invitrogen). The siRNA's were directed against luciferase (siRNA LUC, sequence: CGUACGCGGAAUACUUCGAdTdT) and EGFP (si-EGFP, sequence: CGAGAAGCGCGAU CACAUGdTdT) as negative controls and αB-crystallin (si-αB1, sequence: GCACCCAGCUGGUUUGACAdTdT, si-αB2 sequence: CCCUGAGUCCCUUCUACCUdTdT and si-αB3, sequence: CCGGAUCCCGCUGAUGUAdTdT). After 5 hours, cells were reseeded 4.0×10^4 cells/well in 96-wells plates (6-fold per condition) and 1.25×10^5 cells/well in 6-wells plates (4-fold per condition). The next day, the cells in the 96-wells plates were washed twice with PBS and DMEM (supplemented with GlutaMAX, 1 mM sodiumpyruvate and 10% fetal calf serum) was added containing 0 mM or 5 mM Glucose (Dextrose D(+), Invitrogen). After one hour, cells were kept in the standard incubator or transferred to the H35 hypoxystation maintained at 0.1% O₂ and incubated for 24 hours. All 96-wells plates were subsequently incubated in the standard incubator for 3.5 hours and washed twice with PBS and incubated for two hours in 10-fold diluted Cell Counting Kit-8 solution (Sigma-Aldrich) in Optimem (Invitrogen). The absorbance at 450 nm was measured using an ELISA-reader (Tecan). The cells in the 6-wells plates were harvested 48 hours after siRNA transfection for quantitative RNA analysis to determine the efficiency of αB-crystallin mRNA knockdown.

RNA analysis by quantitative RT-PCR

Total RNA from the harvested UT-SCC-5 and UT-SCC-15 cells was extracted using standard Trizol isolation. After DNase I treatment (Amplification grade, Invitrogen) mRNAs were reverse transcribed using oligo (dT) primers and the Reverse Transcription System (Promega) according to manufacturer's protocol starting with 1 μg of RNA in a final volume of 20 μl. Subsequently, quantitative PCR (qPCR) reactions were performed with 10 μl Power SYBR Green (Applied BioSystems), 5 μM primers and 2 μl cDNA in a final volume of 20 μl. The used primer sequences for αB-crystallin are: ATCTTCTTTTGCGTCGCCAG and TTCCCATGGTGTCTGAGC, and for GAPDH: GATT GAGGTGCATGGAAAC and AGGACCCCATCAGAT GACAG. The fluorescent signal intensities were recorded with the ABI Prism 7000 system (Applied Biosystems). Samples were kept for 10 minutes at 95°C, followed by 40 cycles of 15 seconds at 95°C and 1 minute at 60°C. Data analysis was performed on the CFX96 (Biorad). Analysis was performed with CFX Manager Software (Biorad).

Statistics

Statistical analyses were performed using Graphpad Prism 5.00 software. Statistical analysis was performed using One-way ANOVA and Tukey's Multiple Comparison.

Results

α B-crystallin protein is increased in the hypoxic areas of HNSCC biopsies

The expression of α B-crystallin protein was analyzed in the hypoxic and normoxic regions present in sections of HNSCC biopsies of 38 different patients. To detect the hypoxic regions, the hypoxia marker pimonidazole was used. Figure 1 shows a representative binarized staining of α B-crystallin and pimonidazole (Figure 1A and 1B). Most of the hypoxic areas (Figure 1C, depicted in green) are located in tumor areas at larger distance from blood vessels (Figure 1C, depicted in blue). Interestingly, areas showing α B-crystallin expression (Figure 1C, depicted in red) are largely overlapping with hypoxic areas, though α B-crystallin can be detected in normoxic areas as well. By digital analysis of the scanned images the percentages of α B-crystallin-positive areas in the normoxic tumor areas and in the hypoxic tumor areas were determined for each biopsy. In case hypoxia does not affect α B-crystallin expression, the percentages of α B-crystallin-positive areas present in normoxic and hypoxic areas would be similar (Figure 2, grey line). However, as shown in Figure 2, the percentages of α B-crystallin-positive areas were found to be higher in the hypoxic than in the normoxic areas in all analyzed HNSCC biopsies.

α B-crystallin expression is upregulated by reoxygenation, not hypoxia

The increased presence of α B-crystallin in the hypoxic areas might be the result of two different processes: a stress-induced upregulation of α B-crystallin and/or a longer survival of the cells expressing α B-crystallin. It has been shown that hypoxia stimulates upregulation of

α B-crystallin in piglet stomach, colon and heart tissue [25,26]. For this reason we first tested whether hypoxic incubation is able to increase α B-crystallin mRNA expression levels of HNSCC cell lines by using quantitative RT-PCR. The HNSCC cell line UT-SCC-5 was maintained for 22 hours under 0.1% O₂ conditions and every 2 hours (except t = 12 hours), α B-crystallin mRNA expression levels were determined. Surprisingly, α B-crystallin mRNA levels were found not to be upregulated, but actually 2.3-fold downregulated after 22 hours (Figure 3, P < 0.001), which suggests that the increased expression of α B-crystallin in the hypoxic areas of HNSCC is not directly caused by low oxygen levels. Reoxygenation can also lead to α B-crystallin upregulation, as has been shown in cultured optic nerve astrocytes [32]. Since in some areas hypoxia can be intermittent, resulting in periods with higher oxygen [2-4], we assessed the effect of reoxygenation on α B-crystallin expression. Consistent with the previous experiment, after 48 hours of hypoxic incubation, α B-crystallin mRNA expression was downregulated in UT-SCC-5 as well as in the HNSCC cell line UT-SCC-15 (Figure 4). However, upon reoxygenation, α B-crystallin expression levels were significantly higher than in the cells which were only incubated under normoxic conditions. A similar response was also observed in HeLa cells (data not shown), indicating that this might be a general response.

Next we tested if a similar effect of the reoxygenation could be found on the protein level. For this we could only use the UT-SCC-5 cell line, since α B-crystallin expression in UT-SCC-15 cells was too low to allow detection by western blotting. After 48 hours of hypoxic conditions, α B-crystallin protein levels were decreased






Figure 1 Immunofluorescent staining of human HNSCC for α B-crystallin, pimonidazole-modified proteins and PAL-E. Shown is a representative biopsy section. The fluorescent grey scale images were binarized, resulting in black and white images for α B-crystallin staining (A) and pimonidazole-modified proteins staining, indicating the hypoxic areas (B). The merged image with α B-crystallin staining (assigned red), pimonidazole staining (assigned green) and PAL-E blood vessel staining (assigned blue) shows a substantial overlap between α B-crystallin and hypoxic regions. Hypoxic regions are mostly located in areas at greater distance from vessels (C).






2.0-fold (Figure 5, p < 0.001) and upon reoxygenation the α B-crystallin level was raised 1.5-fold compared to the hypoxic level (p < 0.01). Although the level after reoxygenation did not reach the level observed at normoxic conditions (p < 0.01), these results show that also the α B-crystallin protein was upregulated upon reoxygenation after hypoxia.

α B-crystallin mRNA overexpression during reoxygenation is induced by ROS


Reoxygenation stimulates the production of ROS [33], which at a high concentration is stressful for cells. As a reaction, cells can protect themselves by increasing the level of stress proteins [32]. To test whether ROS induces α B-crystallin expression in HNSCC cells, UT-SCC-5 cells

were treated with H₂O₂. The cells were incubated for 1 hour with a H₂O₂ concentration series between 0 and 3.0 mM H₂O₂ and subsequently harvested after 7 hours (Figure 6). At the protein level no effect could be detected, because the protein expression was too low to allow accurate measurement by western blotting (data not shown). However, a significant increase in α B-crystallin mRNA expression could be observed at 1.5 mM and 3.0 mM H₂O₂, compared to incubation with mock (P < 0.001).





Next, it was tested whether induction of α B-crystallin upon reoxygenation can be reduced with the ROS scavenger NAC. UT-SCC-5 cells were incubated without and with NAC during normoxia, hypoxia and reoxygenation. Without NAC, α B-crystallin mRNA levels were again downregulated during hypoxia and upregulated during reoxygenation, as expected (Figure 7). In the presence of NAC, the hypoxia-induced α B-crystallin mRNA downregulation remained the same, whilst the upregulation upon reoxygenation was reduced 1.7-fold, compared to reoxygenation without NAC. These results suggest that the ROS produced upon reoxygenation is at least in part responsible for the upregulation of α B-crystallin in UT-SCC-5 cells.



α B-crystallin knockdown leads to diminished cell survival under hypoxic and hypoglycemic stress

Next, it was investigated whether cells expressing α B-crystallin were able to survive longer under hypoxic conditions. In hypoxic areas, not only a shortage in oxygen, but hypoglycemia as well is a physiological stressor [34]. Since glucose is able to protect cells under hypoxic conditions [35] and glucose is the main energy source required for HNSCC cell survival [36,37], medium without glucose was used as an additional stress condition. Reduction of α B-crystallin expression in UT-SCC-5 cells was obtained by siRNA-mediated knockdown. Cells with normal and reduced levels of α B-crystallin were exposed to a hypoxic oxygen level of 0.1% for 24 hours, after which the survival was determined by analyzing the cell number with Cell Counting Kit-8. The knockdown of α B-crystallin was performed with 3 different siRNAs and compared with 2 different control siRNAs (Figure 8A). Under normoxic conditions in the presence of 5 mM glucose, knockdown of α B-crystallin did not significantly alter cell survival, although with all three siRNAs a trend in survival reduction was observed (Figure 8B). Hypoxic stress in the presence of 5 mM glucose, led to a significant lower cell survival, compared to normoxic conditions (67% for siEGFP and siLUC). Cell survival could be further reduced significantly, by knockdown of α B-crystallin (57% for si- α B1 and 58% for si- α B2 and si- α B3). Under normoxic conditions, 0 mM glucose led to lower cell survival rates (66% for siEGFP and 63% for si-LUC), which was further reduced as well after knockdown of α B-crystallin (57% for si- α B1 and 55% for si- α B2 and si- α B3). Combining hypoxic as well as hypoglycemia stress was detrimental resulting in 0% cell survival. Since all 3 different α B-crystallin siRNAs gave similar results, it is very unlikely that these observations are due to off-targets effects. These results show that reduction of the α B-crystallin level decreases the survival of hypoxia-exposed and glucose-deprived cells.

Discussion

In the current study, we show that more α B-crystallin protein is present in hypoxic HNSCC tumor areas than in normoxic areas. Since an increased α B-crystallin expression might be the result of a stress-induced transcriptional upregulation, we investigated whether hypoxic stress is able to induce α B-crystallin expression in HNSCC cell lines. Remarkably, under hypoxic conditions α B-crystallin mRNA expression was found to be downregulated in UT-SCC-5 and UT-SCC-15 cells. It is not clear how α B-crystallin is downregulated, but this could be due to a general transcription shutdown caused by epigenetic modifications [38,39]. Only after reoxygenation, a significant upregulation of α B-crystallin mRNA in the HNSCC cell lines was found. The same trend was observed at the protein level. The upregulation of α B-crystallin has also




Figure 8 Knockdown of α B-crystallin expression reduces hypoxia and hypoglycemia survival. Expression of α B-crystallin mRNA in UT-SCC-5 cells was reduced by three different α B-crystallin siRNAs (α B1, α B2 and α B3). LUC and EGFP were used as negative control siRNAs (A). Survival of siRNA-treated UT-SCC-5 cells under normoxic (N) and hypoxic (H, 0.1% O_2 for 24 hours) conditions in the presence of 5 mM or 0 mM glucose (B). Cell survival was assessed via a colorimetric assay using cell counting kit-8. The optical density (O.D.) of siEGFP-treated cells was set at 100%. *** $p < 0.001$, ** $0.001 < p < 0.01$, * $0.01 < p < 0.05$.

been observed in other cell types and by different forms of reoxygenation stress, such as chemical ischemic/recovery stress and ischemic/reperfusion injury [40,41], although from those studies it appeared that the upregulation of α B-crystallin is not a general mechanism since not all cell types show this effect [40]. The reoxygenation-induced upregulation of α B-crystallin also fits with the studies performed with the piglets, where hypoxia-induced α B-crystallin upregulation was detected [25,26]. In these studies piglets were maintained in a hypoxic chamber for either 1 or 4 hours and were allowed to recover over periods of 1 to 68 hours under normoxic condition and thus underwent a period of reoxygenation.

The reoxygenation-induced upregulation of α B-crystallin mRNA is at least partially caused by ROS, based on the inhibitory effect of the ROS-scavenger NAC (Figure 7). Despite the low level of oxygen, significant levels of ROS can be present in hypoxic areas and thus can be responsible for the induction of α B-crystallin expression. ROS-levels in hypoxic areas can be increased by moments of reoxygenation due to intermittent, perfusion-limited hypoxia [9] or produced by necrotic cells which are often present in hypoxic tumor areas [34,42-44]. Also ROS can be produced by a synergistic effect of oncogenic-induced

stimulation of increased mitochondrial capacity and low oxygen levels, which causes an ineffective functioning of mitochondrial respiratory complexes [10]. For this a hypoxia-induced downregulation of thioredoxin reductase 1 seems to be important in maintaining high levels of ROS under hypoxic conditions [45]. As mentioned earlier, some normoxic areas may also contain significant levels of α B-crystallin. These local α B-crystallin expressions might be explained by intermittent hypoxia as well. As shown by Bennewith and colleagues a substantial proportion of tumor cells can go through cycles of hypoxia and normoxia [46,47]. If the intervals of hypoxia are too short or if pimonidazole is not present at the hypoxic moments, erroneously no staining by this marker will be detected [46,47]. Nevertheless, α B-crystallin induced by the ROS formed during the reoxygenation periods might still be present.

α B-crystallin is a stress protein which may enhance cell survival upon ROS exposure, as shown for H_2O_2 treated mouse retinal pigment epithelium cells [48]. Based on knockdown experiments, we showed that α B-crystallin is able to play a role in the survival of cells coping with hypoxia and glucose-deprivation stress as well. It is thus possible that the α B-crystallin present in hypoxic tumor areas plays a role in tumor cell survival during

hypoxic stress [34,49]. This protective activity of α B-crystallin may further increase the number of α B-crystallin-positive cells in hypoxic tumor areas. In summary, the relative higher levels of α B-crystallin in HNSCC hypoxic tumor areas might be caused by a combination of ROS-induced α B-crystallin upregulation and an enhanced survival of α B-crystallin-positive cells exposed to this stress.

The enhanced expression of α B-crystallin in HNSCC may have a negative effect on the prognosis of the patient. We have recently found that α B-crystallin expression is associated with distant metastases formation in HNSCC patients [19]. This association might relate to the chaperone function of α B-crystallin in mediating folding and secretion of VEGF. α B-crystallin is able to bind misfolded vascular endothelial growth factor (VEGF), leading to enhanced VEGF secretion [50,51]. VEGF is specifically upregulated by hypoxia-inducible factor 1 (HIF1) and is important for tumor vascularization. VEGF induction is thus a mechanism to alleviate hypoxic circumstances [52,53]. Cycling hypoxia-induced VEGF expression has been shown to increase pulmonary metastasis formation in mice [54]. Since α B-crystallin can increase hypoxic cell survival and can help in the (re)folding of hypoxia-induced VEGF expression, α B-crystallin expression could ultimately increase the risk of hypoxic tumors to become metastasis-prone [55]. Furthermore, by increasing hypoxic cell survival α B-crystallin may also decrease the sensitivity of a tumor to cancer treatments, such as radiation or other cancer treatments, as shown by the effect of α B-crystallin on tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) as well as cisplatin-induced apoptosis in human ovarian cancer cells [56]. Because of its potential to interfere with anti-tumor therapies, α B-crystallin might be a promising target for anti-cancer treatment.

Conclusions

Enhanced α B-crystallin expression in HNSCC and also in other kind of tumors correlates with poor prognosis of the patients. The underlying stress that induces α B-crystallin expression in HNSCC was not known. Here we show that α B-crystallin is most abundantly present in the hypoxic areas of the tumor, likely caused by ROS stress. The increased expression of α B-crystallin may lead to prolonged survival of hypoxic cells, thereby protecting those cells which are most resistant against cancer treatments.

Abbreviations

HIF1: Hypoxia-inducible factor 1; HNSCC: Head and neck squamous cell carcinoma; NAC: N-acetylcysteine; ROS: Reactive oxygen species; TRAIL: Tumor necrosis factor-related apoptosis-inducing ligand; VEGF: Vascular endothelial growth factor.

Competing interests

The authors have no conflicts of interest to declare.

Authors' contributions

CS participated in the study concept and design, data acquisition of all figures, data analysis and interpretation, statistical analysis, manuscript preparation and editing. ES participated in the data acquisition of Figures 3, 4, 5 and 6, data analysis and interpretation and statistical analysis. JB participated in the study concept and design and manuscript editing. PS participated in study design, data analysis and interpretation, statistical analysis and manuscript editing. RG participated in data acquisition of Figures 3, 4, 5, 6 and 7 and in manuscript reviewing. GP participated in study concept and manuscript reviewing. JK participated in study concept and design and manuscript editing. WB participated in study concept and design, data analysis and interpretation and manuscript editing. All authors read and approved the final manuscript.

Acknowledgements

We would like to thank J. Lok² for staining of the HNSCC tumors and biopsies, H. Stegeman² for generously providing the HNSCC cell lines and the Dutch Cancer Society (KWF) for funding (grant KUN 2007-3864).

Author details

¹Department of Biomolecular Chemistry, Institute for Molecules and Materials and Radboud Institute for Molecular Life Sciences, Radboud University Nijmegen, 271, RIMLS, PO Box 9101, 6500 HB Nijmegen, The Netherlands. ²Department of Radiation Oncology, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands. ³Department of Otorhinolaryngology-Head and Neck Surgery, Turku University Hospital, University of Turku, PO Box 52, FI-20521 Turku, Finland.

Received: 7 October 2013 Accepted: 4 April 2014

Published: 11 April 2014

References

- Harris AL: Hypoxia—a key regulatory factor in tumour growth. *Nat Rev Cancer* 2002, **2**:38–47.
- Liu Y, Song X, Wang X, Wei L, Liu X, Yuan S, Lv L: Effect of chronic intermittent hypoxia on biological behavior and hypoxia-associated gene expression in lung cancer cells. *J Cell Biochem* 2010, **111**:554–563.
- Fukumura D, Duda DG, Munn LL, Jain RK: Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. *Microcirculation* 2010, **17**:206–225.
- Mazzone M, Dettori D, Leite De OR, Loges S, Schmidt T, Jonckx B, Tian YM, Lanahan AA, Pollard P, Ruiz De AC, De SF, Vinckier S, Aragones J, Debackere K, Lutun A, Wyns S, Jordan B, Pisacane A, Gallez B, Lampugnani MG, Dejana E, Simons M, Ratcliffe P, Maxwell P, Carmeliet P: Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. *Cell* 2009, **136**:839–851.
- Chaudary N, Hill RP: Increased expression of metastasis-related genes in hypoxic cells sorted from cervical and lymph nodal xenograft tumors. *Lab Invest* 2009, **89**:587–596.
- Raghunand N, Gatenby RA, Gillies RJ: Microenvironmental and cellular consequences of altered blood flow in tumours. *Br J Radiol* 2003, **1**:S11–S22. 76 Spec No.
- Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW: Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. *Int J Radiat Oncol Biol Phys* 1997, **38**:285–289.
- Zhu X, Zuo L, Cardounel AJ, Zweier JL, He G: Characterization of in vivo tissue redox status, oxygenation, and formation of reactive oxygen species in postischemic myocardium. *Antioxid Redox Signal* 2007, **9**:447–455.
- Prabhakar NR, Kumar GK, Nanduri J, Semenza GL: ROS signaling in systemic and cellular responses to chronic intermittent hypoxia. *Antioxid Redox Signal* 2007, **9**:1397–1403.
- Ralph SJ, Rodriguez-Enriquez S, Neuzil J, Saavedra E, Moreno-Sanchez R: The causes of cancer revisited: "mitochondrial malignancy" and ROS-induced oncogenic transformation - why mitochondria are targets for cancer therapy. *Mol Aspects Med* 2010, **31**:145–170.
- Cooke MS, Evans MD, Dizdaroglu M, Lunec J: Oxidative DNA damage: mechanisms, mutation, and disease. *FASEB J* 2003, **17**:1195–1214.
- Arrigo AP, Simon S, Gibert B, Kretz-Remy C, Nivon M, Czekalla A, Guillet D, Moulin M, Diaz-Latoud C, Vicart P: Hsp27 (HspB1) and α B-crystallin (HspB5) as therapeutic targets. *FEBS Lett* 2007, **581**:3665–3674.

13. Gruvberger-Saal SK, Parsons R: Is the small heat shock protein α B-crystallin an oncogene? *J Clin Invest* 2006, **116**:30–32.
14. Parcellier A, Schmitt E, Brunet M, Hammann A, Solary E, Garrido C: Small heat shock proteins HSP27 and α B-crystallin: cytoprotective and oncogenic functions. *Antioxid Redox Signal* 2005, **7**:404–413.
15. Kamradt MC, Chen F, Sam S, Cryns VL: The small heat shock protein α B-crystallin negatively regulates apoptosis during myogenic differentiation by inhibiting caspase-3 activation. *J Biol Chem* 2002, **277**:38731–38736.
16. Tallot P, Grongnet JF, David JC: Dual perinatal and developmental expression of the small heat shock proteins α B-crystallin and Hsp27 in different tissues of the developing piglet. *Biol Neonate* 2003, **83**:281–288.
17. Chin D, Boyle GM, Williams RM, Ferguson K, Pandeya N, Pedley J, Campbell CM, Theile DR, Parsons PG, Coman WB: α B-crystallin, a new independent marker for poor prognosis in head and neck cancer. *Laryngoscope* 2005, **115**:1239–1242.
18. Mao Y, Zhang DW, Lin H, Xiong L, Liu Y, Li QD, Ma J, Cao Q, Chen RJ, Zhu J, Feng ZQ: α B-crystallin is a new prognostic marker for laryngeal squamous cell carcinoma. *J Exp Clin Cancer Res* 2012, **31**:101.
19. van de Schootbrugge C, Bussink J, Span PN, Sweep FC, Grenman R, Stegeman H, Pruijn GJ, Kaanders JH, Boelens WC: α B-crystallin stimulates VEGF secretion and tumor cell migration and correlates with enhanced distant metastasis in head and neck squamous cell carcinoma. *BMC Cancer* 2013, **13**:128.
20. Moyano JV, Evans JR, Chen F, Lu M, Werner ME, Yehiely F, Diaz LK, Turbin D, Karaca G, Wiley E, Nielsen TO, Perou CM, Cryns VL: α B-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. *J Clin Invest* 2006, **116**:261–270.
21. Sitterding SM, Wiseman WR, Schiller CL, Luan C, Chen F, Moyano JV, Watkin WG, Wiley EL, Cryns VL, Diaz LK: α B-crystallin: a novel marker of invasive basal-like and metaplastic breast carcinomas. *Ann Diagn Pathol* 2008, **12**:33–40.
22. Chelouche-Lev D, Kluger HM, Berger AJ, Rimm DL, Price JE: α B-crystallin as a marker of lymph node involvement in breast carcinoma. *Cancer* 2004, **100**:2543–2548.
23. Kim HS, Lee Y, Lim YA, Kang HJ, Kim LS: α B-Crystallin is a Novel Oncoprotein Associated with Poor Prognosis in Breast Cancer. *J Breast Cancer* 2011, **14**:14–19.
24. Van De Schootbrugge C, Boelens WC: Introduction to Small Heat Shock Proteins. In *Small Stress Proteins and Human Diseases*. Edited by Simon S, Arrigo AP. New York: Nova Science Publishers. Protein Science and Engineering; 2010:1–27.
25. Louapre P, Grongnet JF, Tanguay RM, David JC: Effects of hypoxia on stress proteins in the piglet heart at birth. *Cell Stress Chaperones* 2005, **10**:17–23.
26. Nefti O, Grongnet JF, David JC: Overexpression of α B-crystallin in the gastrointestinal tract of the newborn piglet after hypoxia. *Shock* 2005, **24**:455–461.
27. Hoogsteen IJ, Marres HA, Wijffels KJ, Rijken PF, Peters JP, van den Hoogen FJ, Oosterwijk E, van der Kogel AJ, Kaanders JH: Colocalization of carbonic anhydrase 9 expression and cell proliferation in human head and neck squamous cell carcinoma. *Clin Cancer Res* 2005, **11**:97–106.
28. Van De Klundert FA, Gijsen ML, Van Den IJssel PR, Snoeckx LH, De Jong WW: α B-crystallin and hsp25 in neonatal cardiac cells—differences in cellular localization under stress conditions. *Eur J Cell Biol* 1998, **75**:38–45.
29. Wessel GM, McClay DR: Two embryonic, tissue-specific molecules identified by a double-label immunofluorescence technique for monoclonal antibodies. *J Histochem Cytochem* 1986, **34**:703–706.
30. Rademakers SE, Lok J, van der Kogel AJ, Bussink J, Kaanders JH: Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1 α , CAIX, LDH-5, GLUT-1, MCT1 and MCT4. *BMC Cancer* 2011, **11**:167.
31. Yaromina A, Zips D, Thames HD, Eicheler W, Krause M, Rosner A, Haase M, Petersen C, Raleigh JA, Quennet V, Walenta S, Mueller-Klieser W, Baumann M: Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: the need for a multivariate approach in biomarker studies. *Radiother Oncol* 2006, **81**:122–129.
32. Yu AL, Fuchshofer R, Birke M, Priglinger SG, Eibl KH, Kampik A, Bloemendal H, Welge-Lüssen U: Hypoxia/reoxygenation and TGF- β increase α B-crystallin expression in human optic nerve head astrocytes. *Exp Eye Res* 2007, **84**:694–706.
33. Li C, Jackson RM: Reactive species mechanisms of cellular hypoxia-reoxygenation injury. *Am J Physiol Cell Physiol* 2002, **282**:C227–C241.
34. Onozuka H, Tsuchihara K, Esumi H: Hypoglycemic/hypoxic condition in vitro mimicking the tumor microenvironment markedly reduced the efficacy of anticancer drugs. *Cancer Sci* 2011, **102**:975–982.
35. Malhotra R, Brosius FC III: Glucose uptake and glycolysis reduce hypoxia-induced apoptosis in cultured neonatal rat cardiac myocytes. *J Biol Chem* 1999, **274**:12567–12575.
36. Sandulache VC, Ow TJ, Pickering CR, Frederick MJ, Zhou G, Fokt I, Vis Malesevich M, Priebe W, Myers JN: Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. *Cancer* 2011, **117**:2926–2938.
37. Meijer TW, Kaanders JH, Span PN, Bussink J: Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. *Clin Cancer Res* 2012, **18**:5585–5594.
38. Perez-Perri JJ, Acevedo JM, Wappner P: Epigenetics: new questions on the response to hypoxia. *Int J Mol Sci* 2011, **12**:4705–4721.
39. Johnson AB, Denko N, Barton MC: Hypoxia induces a novel signature of chromatin modifications and global repression of transcription. *Mutat Res* 2008, **640**:174–179.
40. Imura T, Shimohama S, Sato M, Nishikawa H, Madono K, Akaike A, Kimura J: Differential expression of small heat shock proteins in reactive astrocytes after focal ischemia: possible role of beta-adrenergic receptor. *J Neurosci* 1999, **19**:9768–9779.
41. Li T, Mo X, Jiang Z, He W, Lu W, Zhang H, Zhang J, Zeng L, Yang B, Xiao H, Hu Z: Study of α B-crystallin expression in Gerbil BCSO model of transient global cerebral ischemia. *Oxid Med Cell Longev* 2012, **2012**:945071.
42. Bertuzzi A, Fasano A, Gandolfi A, Sinisgalli C: Necrotic core in EMT6/Ro tumour spheroids: Is it caused by an ATP deficit? *J Theor Biol* 2010, **262**:142–150.
43. Takahashi E: Anoxic cell core can promote necrotic cell death in cardiomyocytes at physiological extracellular PO₂. *Am J Physiol Heart Circ Physiol* 2008, **294**:H2507–H2515.
44. Morgan MJ, Kim YS, Liu ZG: TNF α and reactive oxygen species in necrotic cell death. *Cell Res* 2008, **18**:343–349.
45. Naranjo Suarez S, Carlson BA, Tsuji PA, Yoo MH, Gladyshev VN, Hatfield DL: HIF-independent regulation of thioredoxin reductase 1 contributes to the high levels of reactive oxygen species induced by hypoxia. *PLoSOne* 2012, **7**:e30470.
46. Bennewith KL, Raleigh JA, Durand RE: Orally administered pimonidazole to label hypoxic tumor cells. *Cancer Res* 2002, **62**:6827–6830.
47. Bennewith KL, Durand RE: Quantifying transient hypoxia in human tumor xenografts by flow cytometry. *Cancer Res* 2004, **64**:6183–6189.
48. Yaung J, Jin M, Barron E, Spee C, Wawrousek EF, Kannan R, Hinton DR: α -Crystallin distribution in retinal pigment epithelium and effect of gene knockouts on sensitivity to oxidative stress. *Mol Vis* 2007, **13**:566–577.
49. Vaupel P: Tumor microenvironmental physiology and its implications for radiation oncology. *Semin Radiat Oncol* 2004, **14**:198–206.
50. Kase S, He S, Sonoda S, Kitamura M, Spee C, Wawrousek E, Ryan SJ, Kannan R, Hinton DR: α B-crystallin regulation of angiogenesis by modulation of VEGF. *Blood* 2010, **115**:3398–3406.
51. Kerr BA, Byzova TV: α B-crystallin: a novel VEGF chaperone. *Blood* 2010, **115**:3181–3183.
52. Martiny-Baron G, Marme D: VEGF-mediated tumour angiogenesis: a new target for cancer therapy. *Curr Opin Biotechnol* 1995, **6**:675–680.
53. Jung JE, Lee HG, Cho IH, Chung DH, Yoon SH, Yang YM, Lee JW, Choi S, Park JW, Ye SK, Chung MH: STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells. *FASEB J* 2005, **19**:1296–1298.
54. Rofstad EK, Gaustad JV, Egeland TA, Mathiesen B, Galappathi K: Tumors exposed to acute cyclic hypoxic stress show enhanced angiogenesis, perfusion and metastatic dissemination. *Int J Cancer* 2010, **127**:1535–1546.
55. Chaudary N, Hill RP: Hypoxia and metastasis. *Clin Cancer Res* 2007, **13**:1947–1949.
56. Volkman J, Reuning U, Rudelius M, Hafner N, Schuster T, AB VR, Weimer J, Hilpert F, Kiechle M, Durst M, Arnold N, Schmalfeldt B, Meindl A, Ramser J: High expression of crystallin α B represents an independent molecular marker for unfavourable ovarian cancer patient outcome and impairs T. *Int J Cancer* 2013, **132**:2820–2832.

doi:10.1186/1471-2407-14-252

Cite this article as: van de Schootbrugge et al.: Effect of hypoxia on the expression of α B-crystallin in head and neck squamous cell carcinoma. *BMC Cancer* 2014 **14**:252.